SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

BMO Capital Cuts Neurocrine Price Target to $150 From $164

BMO Capital maintained its Market Perform rating on Neurocrine.

NBIX